Cd19 pe cy7 sj25c1

Manufactured by BD

Sourced in United States

CD19-PE-Cy7 (SJ25C1) is a fluorescently-labeled monoclonal antibody designed for the detection of CD19 expression on cells. It is a laboratory tool intended for research use only.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

CD19-PE (90 citations) CD19-PE-Cy7 (83 citations) CD19 (SJ25C1, (11 citations) CD19 PE-Cy7 (clone SJ25C1, (3 citations) PE Cy7; SJ25C1 (2 citations)

4 protocols using cd19 pe cy7 sj25c1

Comprehensive B Cell Immunophenotyping

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Absolute counts of blood CD4 and CD8 T cells, CD16⁺/56⁺ natural killer cells, and CD19⁺ B cells were obtained with a diagnostic lyse-no-wash protocol. Eight-color flow cytometric analysis was performed as described previously to detect transitional, naive mature, six memory B cell subsets, plasmablasts and CD21^lowCD38^dim cells (S1 Fig) on a 3-laser FACS LSRII with standardized configuration according to Euroflow protocols (BD Biosciences, San Jose, CA) [23 (link)]. Detailed analysis of B cell subsets was performed with IgM-HorV450 (G20-127; BD), IgD-biotin (IA6-2), IgG-PE (G18-145), CD19-PE-Cy7 (SJ25C1), CD19-PerCP-Cy5.5 (SJ25C1), CD21-PE-Cy7 (B-ly4), CD27-PerCP-Cy5.5 (L128), CD27-APC (L128), CD38-APC-H7 (HB7; all from BD Biosciences, San Jose, CA, USA) and IgA-FITC (IS11-8E10; Miltenyi-Biotec GmbH, Germany) [24 (link)]. Biotinylated antibodies were visualized with streptavidin-Pac.Orange (Invitrogen).
Naive mature and natural effector B cells were high-speed cell sorted to greater than 95% purity on a FACSAria I (BD Biosciences), as described previously [25 (link)].

Timmermans W.M., van Laar J.A., van der Houwen T.B., Kamphuis L.S., Bartol S.J., Lam K.H., Ouwendijk R.J., Sparrow M.P., Gibson P.R., van Hagen P.M, & van Zelm M.C. (2016). B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS ONE, 11(7), e0160103.

+ Open protocol

+ Expand

Purification and Characterization of B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 100,000 purified B cells were stained with antibodies against CD14-PacB (M5E2), CD3-PacB (UCHT1) and CD19 PE-Cy7 (SJ25C1) (all from BD Biosciences, San Jose, CA, USA) for 15 minutes at 4 °C. Afterward, 4′,6-diamidino-2-phenylindole (DAPI) was added to the stained cells (dead cell staining) and analyzed by FC using a FACSCanto II flow cytometer (BD Biosciences). Data were evaluated using FlowJo software (version 7; Tree Star, Ashland, OR, USA). The total B cell (CD3⁻CD14⁻DAPI⁻CD19⁺) purity was 98.5 ± 2.2 % in almost all samples (mean ± standard deviation), with the exception of two cases with 8.2 % and 5.6 % non–B cells (CD3⁺ cells, CD14⁺ cells or cell debris). These two samples were outliers but did not show any results substantially different from the remaining samples. Additional analyses also did not show any relationship between cytokine levels in the supernatants of TNF-α, IL-6 or IL-10 and the frequency of non-B cells of these samples, including any relationship of the impact of epratuzumab and the frequency of non-B cells after purification (data not shown).

Fleischer V., Sieber J., Fleischer S.J., Shock A., Heine G., Daridon C, & Dörner T. (2015). Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. Arthritis Research & Therapy, 17(1), 185.

+ Open protocol

+ Expand

Comprehensive Immunophenotyping of Bone Marrow

Check if the same lab product or an alternative is used in the 5 most similar protocols

For immunophenotyping, BM cells were treated with RBC Lysis Buffer (BioLegend, San Diego, CA, USA) and stained with the following monoclonal antibodies: anti-human CD45-Allophycocyanin (Clone: HI30), CD34-phycoerythrin (PE; 581), CD19-PEcy7 (SJ25C1; BD Biosciences, San Jose, CA, USA), hCD33-PerCPcy5.5 (P67.6), and anti-mouse CD45-Brilliant Violet 605 (30-F11; BioLegend) [24 ]. 4′,6-diamidino-2-phenylindole (DAPI) was used to identify dead cell. All flow cytometric analyses were performed with BD LSR Fortessa (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR, USA). In singlet population of live cells, the percentage of human CD45⁺ cells was calculated as [% hCD45⁺/(% hCD45⁺ + % mCD45⁺) x 100] and gating for percentages of human CD34⁺, CD19⁺ and CD33⁺ were performed on the human CD45⁺ population.

Jang Y., Kim Y.S., Wielgosz M.M., Ferrara F., Ma Z., Condori J., Palmer L.E., Zhao X., Kang G., Rawlings D.J., Zhou S, & Ryu B.Y. (2020). Optimizing Lentiviral Vector Transduction of Hematopoietic Stem Cells for Gene Therapy. Gene therapy, 27(12), 545-556.

+ Open protocol

+ Expand

Longitudinal Immune Profiling in Humanized Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunophenotyping was performed on peripheral blood samples collected longitudinally and at the study endpoint on whole blood and on mononuclear cells isolated from the tissues of humanized mice. Prior to antibody incubation, Ig-binding sites were blocked. The fluorochrome-conjugated antibodies included CD45-V500 (HI30, BD Biosciences, San Jose, USA), CD3-APC-R700 (UCHT1, BD Biosciences, San Jose, USA), CD4-APC-H7 (RPA-T4, BD Biosciences, San Jose, USA), CD8-FITC (SK1, BD Biosciences, San Jose, USA), CD19-PE-Cy7 (SJ25C1, BD Biosciences, San Jose, USA), CD27-PE (M-T271, BD Biosciences, San Jose, USA), CD38-APC (HB7, BD Biosciences, San Jose, USA), CD45RA-Pacific Blue (F8-11-13, Bio-Rad, Hercules, USA), HLA-DR-PerCP (L243, BD Biosciences, San Jose, USA), mouse IgG1k-APC (MOPC-21, BD Biosciences, San Jose, USA), mouse IgG1k- Pacific Blue (MOPC-21, BD Biosciences, San Jose, USA), mouse IgG1k-PE (MOPC-21, BD Biosciences, San Jose, USA) and mouse IgG2ak-PerCP (X39, BD Biosciences, San Jose, USA). After antibody incubation, blood samples were lysed with t 1× BD FACS lysing solution (BD Biosciences, San Jose, USA). Samples were then analyzed on a BD LSRFortessa instrument (BD Biosciences, San Jose, USA).

Ling L., Leda A.R., Begum N., Spagnuolo R.A., Wahl A., Garcia J.V, & Valente S.T. (2023). Loss of In Vivo Replication Fitness of HIV-1 Variants Resistant to the Tat Inhibitor, dCA. Viruses, 15(4), 950.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!